Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea

Kathryn J. Ruddy, Daniel J. Schaid, Anthony Batzler, Reena S. Cecchini, Ann H. Partridge, Aaron Norman, Louis Fehrenbacher, Elizabeth A. Stewart, Emanuel Trabuco, Elizabeth Ginsburg, Fergus J. Couch, Peter A. Fasching, Celine Vachon, Patricia A. Ganz

Research output: Contribution to journalArticlepeer-review


Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age ¼ 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicincyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.

Original languageEnglish (US)
Pages (from-to)1105-1108
Number of pages4
JournalJournal of the National Cancer Institute
Issue number8
StatePublished - Aug 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea'. Together they form a unique fingerprint.

Cite this